George Simeakis | Medicine and Health Sciences | Best Researcher Award

Posted on by Popular Scientist

Dr. George Simeakis | Medicine and Health Sciences | Best Researcher Award

Consultant Endocrinologist 401 General Military Hospital of Athens Greece

Dr. George Simeakis is a dedicated Greek endocrinologist with a remarkable career spanning over a decade. Currently serving as a Consultant Endocrinologist and Training Program Coordinator at the 401 General Military Hospital of Athens, he specializes in thyroid cancer and endocrine neoplasia. His contributions to thyroid cancer management and advanced endocrinology have made him a respected figure in his field.

Profile

Scopus

Orcid

Education 🎓

  • Ph.D. (Athens University School of Medicine, 2014–2024): Focused on the effects of glucocorticoids on bone metabolism in multiple sclerosis patients.
  • Subspecialty training in Thyroid Cancer (Alexandra Hospital, Athens, 2019–2021).
  • Visiting Fellow (Thyroid Oncology, Pisa, Italy, 2021).
  • Residency in Endocrinology (Alexandra Hospital, Athens).
  • Residency in Internal Medicine (401 General Military Hospital, Athens).

Experience 💼

  • Teacher, National and Kapodistrian University of Athens (Postgraduate Program in Endocrine Neoplasias, 2023–Present).
  • Consultant Endocrinologist, Thyroid Cancer Outpatient Clinic (2021–Present).
  • Training Program Coordinator, 401 General Military Hospital.
  • Private Practice Endocrinologist (Since 2013).
  • Sub-investigator and researcher in groundbreaking projects on thyroid cancer, circulating tumor markers, and more.

Research Interests 🔬

Dr. Simeakis’s research focuses on:

  • Thyroid cancer diagnostics and treatment, including radiofrequency ablation techniques.
  • Circulating tumor DNA (ctDNA) and cells (CTCs) in endocrine malignancies.
  • Bone health in autoimmune disorders like multiple sclerosis.

Awards & Honors 🏆

  • D. Ikkos Award (2024): Best publication in clinical endocrinology.
  • Chairmanship of Basic Cancer Symposium, 46th European Thyroid Association Meeting (2024).
  • Discussion Leader, Medullary Thyroid Cancer Poster Session (2024).

Publications Top Notes: 📚

“Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece”
Biomedicines, 2025. Read here
Cited by: 12 articles.

“Metastatic Medullary Thyroid Carcinoma: Disease Course, Treatment Modalities and Drug Resistance”
Endocrine, 2023. Read here
Cited by: 25 articles.

“High-Dose Intravenous Steroid Treatment in Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study”
Biomedicines, 2023. Read here
Cited by: 15 articles.

“Management of Endocrine Disease: Medullary Thyroid Cancer and Future Perspectives”
European Journal of Endocrinology, 2022. Read here
Cited by: 20 articles.

 

Jan Vorwerk | Medicine and Health Sciences | Young Scientist Award

Posted on by Popular Scientist

Dr. Jan Vorwerk | Medicine and Health Sciences | Young Scientist Award

Resident Physician University Cancer Center Schleswig-Holstein (UCCSH) Germany

Dr. Jan Vorwerk is a distinguished medical researcher and clinician currently serving as a resident physician and clinician scientist at the Department of Hematology and Oncology, University Cancer Center Schleswig-Holstein (UCCSH), Germany. With a summa cum laude distinction for his medical doctorate and over five years of advanced medical training across Germany, Canada, and Switzerland, Dr. Vorwerk has made remarkable contributions to hematology and oncology research, particularly in acute myeloid leukemia (AML).

Profile

Scopus

Education 🎓

Dr. Vorwerk completed his Medical Doctorate at the University of Münster, with a groundbreaking thesis on the role of GFI1-36N polymorphism in DNA repair and AML therapy, earning summa cum laude honors. He is also a proud alumnus of the University of Zürich and McMaster University. His rigorous academic journey includes first-class grades in multiple state exams and prestigious scholarships from organizations like the German Academic Scholarship Foundation.

Experience 🏥

Dr. Vorwerk’s professional journey includes significant roles as a scholar at the Jürgen Manchot Foundation and the Interdisciplinary Center for Clinical Research Münster. Currently, he is at the forefront of clinical and molecular research in oncology as a resident physician at UCCSH, where he integrates cutting-edge therapies with patient care.

Research Interests 🔬

Dr. Vorwerk specializes in molecular hematology and oncology, focusing on the genetic and metabolic underpinnings of acute myeloid leukemia (AML). His research explores polymorphisms affecting DNA repair, mitochondrial function, and innovative therapeutic targets like CDK4/6 inhibition in leukemia and multiple myeloma.

Awards 🏆

Dr. Vorwerk has been recognized with numerous accolades, including the “Anne Frank Ambassador Award” for academic excellence and community leadership, the “Abitur Graduate Prize” from North Rhine-Westphalia, and scientific honors like the “Young People’s Award” and multiple international science fair prizes.

Publications Top Notes: 📚

Dr. Vorwerk has authored several impactful publications:

Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition. Front Oncol. 2022;12:903691.

Germline single-nucleotide polymorphism GFI1-36N causes alterations in mitochondrial metabolism and leads to increased ROS-mediated DNA damage in AML. Biomedicines. 2025;13:107.

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to therapy. Blood. 2023;142(25):2175-2191.